Ono Pharmaceutical Co., Ltd. (4528) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Astellas Pharma, Inc.

Kyowa Kirin Co., Ltd.

Shionogi & Co., Ltd.

Ono Pharmaceutical Co., Ltd.

Otsuka Holdings Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

Daiichi Sankyo Co., Ltd.

Eisai Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Why is Ono Pharmaceutical Co., Ltd. ?

With a growth in Net Profit of 37.31%, the company declared Very Positive results in Jun 26

The company has declared positive results for the last 3 consecutive quarters
NET PROFIT(HY) At JPY 24,969 MM has Grown at 126.09%
OPERATING CASH FLOW(Y) Highest at JPY 134,501 MM
RAW MATERIAL COST(Y) Fallen by -6.19% (YoY)

With ROE of 8.22%, it has a very attractive valuation with a 1.32 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 39.86%, its profits have risen by 39.4% ; the PEG ratio of the company is 0.4
At the current price, the company has a high dividend yield of 0

Majority shareholders : FIIs

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Ono Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Ono Pharmaceutical Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Ono Pharmaceutical Co., Ltd.

41.67%

0.22

26.67%

Japan Nikkei 225

60.14%

2.04

29.37%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

10.77%

EBIT Growth (5y)

2.33%

EBIT to Interest (avg)

92.07

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.09

Sales to Capital Employed (avg)

0.55

Tax Ratio

24.55%

Dividend Payout Ratio

53.88%

Pledged Shares

Institutional Holding

0.04%

ROCE (avg)

19.84%

ROE (avg)

12.49%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.32

EV to EBIT

9.69

EV to EBITDA

7.10

EV to Capital Employed

1.38

EV to Sales

1.94

PEG Ratio

0.41

Dividend Yield

ROCE (Latest)

14.24%

ROE (Latest)

8.22%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

NET PROFIT(HY)

At JPY 24,969 MM has Grown at 126.09%

OPERATING CASH FLOW(Y)

Highest at JPY 134,501 MM

RAW MATERIAL COST(Y)

Fallen by -6.19% (YoY

CASH AND EQV(HY)

Highest at JPY 459,868 MM

DEBT-EQUITY RATIO (HY)

Lowest at -12.01 %

DEBTORS TURNOVER RATIO(HY)

Highest at 3.67 times

OPERATING PROFIT MARGIN(Q)

Highest at 34.57 %

-3What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.11 times

NET SALES(Q)

Lowest at JPY 116,160 MM

Here's what is working for Ono Pharmaceutical Co., Ltd.

Net Profit

At JPY 24,969 MM has Grown at 126.09%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (JPY MM)

Operating Cash Flow

Highest at JPY 134,501 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (JPY MM)

Operating Profit Margin

Highest at 34.57 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Cash and Eqv

Highest at JPY 459,868 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -12.01 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 3.67 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -6.19% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Ono Pharmaceutical Co., Ltd.

Net Sales

Lowest at JPY 116,160 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (JPY MM)

Net Sales

Fallen at -8.92%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (JPY MM)

Inventory Turnover Ratio

Lowest at 2.11 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio